Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 18/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13822111 | 0.89 | ELANE (0.51) | ELANE | |
| SCHEMBL7007704 | 0.88 | ELANE (0.55) | ELANE | |
| SCHEMBL13299879 | 0.85 | ELANE (0.52) | ELANE | |
| SCHEMBL7002405 | 0.84 | ELANE (0.48) | ELANE | |
| SCHEMBL10299169 | 0.78 | ELANE (0.51) | ELANE | |
| SCHEMBL13014698 | 0.78 | ELANE (0.51) | ELANE | |
| SCHEMBL13814746 | 0.78 | ELANE (0.50) | ELANE | |
| SCHEMBL13822260 | 0.78 | ELANE (0.44) | ELANE | |
| SCHEMBL5801511 | 0.78 | ELANE (0.63) | ELANE | |
| SCHEMBL7373453 | 0.78 | ELANE (0.63) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030216324-A1 | Airway mucus secretion inhibitors | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-11-20 | — | — | US | claimed |
| US-20030212115-A1 | Remedies for inflammatory bowel diseases | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-11-13 | — | — | US | claimed |
| EP-1323419-A1 | AIRWAY MUCUS SECRETION INHIBITORS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-07-02 | — | — | EP | claimed |
| EP-1323420-A1 | REMEDIES FOR INFLAMMATORY BOWEL DISEASES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-07-02 | — | — | EP | claimed |
| US-20030216324-A1 | Airway mucus secretion inhibitors | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-11-20 | — | — | US | disclosed |
| US-20030212115-A1 | Remedies for inflammatory bowel diseases | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-11-13 | — | — | US | disclosed |
| EP-1323420-A1 | REMEDIES FOR INFLAMMATORY BOWEL DISEASES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-07-02 | — | — | EP | disclosed |
| EP-1323419-A1 | AIRWAY MUCUS SECRETION INHIBITORS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212115-A1 | Remedies for inflammatory bowel diseases | NOS3, TPMT, NOS2 | ELANE 588/4885 |
| US-20030216324-A1 | Airway mucus secretion inhibitors | MUC1, CFTR, SERPINB1 | ELANE 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.